246 related articles for article (PubMed ID: 36675134)
1. Cytoplasmic Expression of TP53INP2 Modulated by Demethylase FTO and Mutant NPM1 Promotes Autophagy in Leukemia Cells.
Huang J; Sun M; Tao Y; Ren J; Peng M; Jing Y; Xiao Q; Yang J; Lin C; Lei L; Yang Z; Zhang L
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675134
[TBL] [Abstract][Full Text] [Related]
2. Cytoplasmic TP53INP2 acts as an apoptosis partner in TRAIL treatment: the synergistic effect of TRAIL with venetoclax in TP53INP2-positive acute myeloid leukemia.
Ren J; Huang J; Yang Z; Sun M; Yang J; Lin C; Jin F; Liu Y; Tang L; Hu J; Wei X; Chen X; Yuan Z; Yang Z; Chen Y; Zhang L
J Exp Clin Cancer Res; 2024 Jun; 43(1):176. PubMed ID: 38909249
[TBL] [Abstract][Full Text] [Related]
3. Mutant NPM1-regulated lncRNA HOTAIRM1 promotes leukemia cell autophagy and proliferation by targeting EGR1 and ULK3.
Jing Y; Jiang X; Lei L; Peng M; Ren J; Xiao Q; Tao Y; Tao Y; Huang J; Wang L; Tang Y; Yang Z; Yang Z; Zhang L
J Exp Clin Cancer Res; 2021 Oct; 40(1):312. PubMed ID: 34615546
[TBL] [Abstract][Full Text] [Related]
4. Glycolytic Enzyme PKM2 Mediates Autophagic Activation to Promote Cell Survival in NPM1-Mutated Leukemia.
Wang L; Yang L; Yang Z; Tang Y; Tao Y; Zhan Q; Lei L; Jing Y; Jiang X; Jin H; Zou Q; Xian J; Zhang L
Int J Biol Sci; 2019; 15(4):882-894. PubMed ID: 30906218
[TBL] [Abstract][Full Text] [Related]
5. TP53INP2 contributes to autophagosome formation by promoting LC3-ATG7 interaction.
You Z; Xu Y; Wan W; Zhou L; Li J; Zhou T; Shi Y; Liu W
Autophagy; 2019 Aug; 15(8):1309-1321. PubMed ID: 30767704
[TBL] [Abstract][Full Text] [Related]
6. NPM1 mutant maintains ULK1 protein stability via TRAF6-dependent ubiquitination to promote autophagic cell survival in leukemia.
Tang Y; Tao Y; Wang L; Yang L; Jing Y; Jiang X; Lei L; Yang Z; Wang X; Peng M; Xiao Q; Ren J; Zhang L
FASEB J; 2021 Feb; 35(2):e21192. PubMed ID: 33201521
[TBL] [Abstract][Full Text] [Related]
7. NPM1 Mutant Mediated PML Delocalization and Stabilization Enhances Autophagy and Cell Survival in Leukemic Cells.
Zou Q; Tan S; Yang Z; Zhan Q; Jin H; Xian J; Zhang S; Yang L; Wang L; Zhang L
Theranostics; 2017; 7(8):2289-2304. PubMed ID: 28740552
[TBL] [Abstract][Full Text] [Related]
8. Mutant NPM1 maintains RASGRP3 protein stability via interaction with MID1 to promote acute myeloid leukemia cell proliferation and autophagy.
Wang Y; Pan C; Zhang X; Zhao A; Dong Y
J Leukoc Biol; 2023 May; 113(5):504-517. PubMed ID: 36826998
[TBL] [Abstract][Full Text] [Related]
9. Mutant NPM1-Regulated FTO-Mediated m
Xiao Q; Lei L; Ren J; Peng M; Jing Y; Jiang X; Huang J; Tao Y; Lin C; Yang J; Sun M; Tang L; Wei X; Yang Z; Zhang L
Front Oncol; 2022; 12():817584. PubMed ID: 35211409
[TBL] [Abstract][Full Text] [Related]
10. CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice.
Martelli MP; Pettirossi V; Thiede C; Bonifacio E; Mezzasoma F; Cecchini D; Pacini R; Tabarrini A; Ciurnelli R; Gionfriddo I; Manes N; Rossi R; Giunchi L; Oelschlägel U; Brunetti L; Gemei M; Delia M; Specchia G; Liso A; Di Ianni M; Di Raimondo F; Falzetti F; Del Vecchio L; Martelli MF; Falini B
Blood; 2010 Nov; 116(19):3907-22. PubMed ID: 20634376
[TBL] [Abstract][Full Text] [Related]
11. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications.
Falini B; Bolli N; Liso A; Martelli MP; Mannucci R; Pileri S; Nicoletti I
Leukemia; 2009 Oct; 23(10):1731-43. PubMed ID: 19516275
[TBL] [Abstract][Full Text] [Related]
12. Imidazoquinoxaline derivative EAPB0503: A promising drug targeting mutant nucleophosmin 1 in acute myeloid leukemia.
Nabbouh AI; Hleihel RS; Saliba JL; Karam MM; Hamie MH; Wu HJM; Berthier CP; Tawil NM; Bonnet PA; Deleuze-Masquefa C; El Hajj HA
Cancer; 2017 May; 123(9):1662-1673. PubMed ID: 28055106
[TBL] [Abstract][Full Text] [Related]
13. NPM1-mutated acute myeloid leukemia: New pathogenetic and therapeutic insights and open questions.
Falini B
Am J Hematol; 2023 Sep; 98(9):1452-1464. PubMed ID: 37317978
[TBL] [Abstract][Full Text] [Related]
14. A Curious Novel Combination of
Venanzi A; Rossi R; Martino G; Annibali O; Avvisati G; Mameli MG; Sportoletti P; Tiacci E; Falini B; Martelli MP
Genes (Basel); 2021 Sep; 12(9):. PubMed ID: 34573408
[No Abstract] [Full Text] [Related]
15. Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant with NPM1 mutation and is not predictive of prognosis.
Konoplev S; Huang X; Drabkin HA; Koeppen H; Jones D; Kantarjian HM; Garcia-Manero G; Chen W; Medeiros LJ; Bueso-Ramos CE
Cancer; 2009 Oct; 115(20):4737-44. PubMed ID: 19637342
[TBL] [Abstract][Full Text] [Related]
16. The effect of small molecule inhibitor NSC348884 on nucleophosmin 1-mutated acute myeloid leukemia cells.
Zhu JF; Han LL; Ma Y; Wang YX; Zhang F
Eur Rev Med Pharmacol Sci; 2023 Oct; 27(19):9145-9151. PubMed ID: 37843328
[TBL] [Abstract][Full Text] [Related]
17. Nucleophosmin 1 Mutations in Acute Myeloid Leukemia.
Zarka J; Short NJ; Kanagal-Shamanna R; Issa GC
Genes (Basel); 2020 Jun; 11(6):. PubMed ID: 32545659
[TBL] [Abstract][Full Text] [Related]
18. Acute myeloid leukemia with mutated nucleophosmin (NPM1): any hope for a targeted therapy?
Falini B; Gionfriddo I; Cecchetti F; Ballanti S; Pettirossi V; Martelli MP
Blood Rev; 2011 Nov; 25(6):247-54. PubMed ID: 21724308
[TBL] [Abstract][Full Text] [Related]
19. A novel leukemic route of mutant NPM1 through nuclear import of the overexpressed long noncoding RNA LONA.
Gourvest M; De Clara E; Wu HC; Touriol C; Meggetto F; De Thé H; Pyronnet S; Brousset P; Bousquet M
Leukemia; 2021 Oct; 35(10):2784-2798. PubMed ID: 34131282
[TBL] [Abstract][Full Text] [Related]
20. A dose-dependent tug of war involving the NPM1 leukaemic mutant, nucleophosmin, and ARF.
Bolli N; De Marco MF; Martelli MP; Bigerna B; Pucciarini A; Rossi R; Mannucci R; Manes N; Pettirossi V; Pileri SA; Nicoletti I; Falini B
Leukemia; 2009 Mar; 23(3):501-9. PubMed ID: 19005479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
